NLS Days, Malmö, Sweden, September 10-12, 2019

Please meet us at the Nordic Life Science Days 2019 in Malmö, Sweden, on September 10th to 12th. NLS Days is the largest Nordic partnering conference dedicated to the life science industry. NLS Days offers networking and knowledge for anyone interested in the Nordic life science, biotech, pharma, medical devices and e-health business.
(March 2019)

BioPharm America, Boston, USA, September 11-12, 2019

Please meet us at BioPharm America 2019 in Boston on September 11th and 12th. Bio Pharm America is where life science leaders partner and accelerate growth. Build strategic partnerships and grow your knowledge with the brightest minds in biotech, pharma and finance. Network with new and renewed relationships at evening events and receptions and meet cutting edge startup companies from top innovation clusters.
(March 2019)

International Pharma Licensing Symposium, Paris, France, September 18-20, 2019

Please meet us at the 15th International Pharma Licensing Symposium in Paris, France, from September 18th to 20th 2019. The IPLS event is a great opportunity for the healthcare deal-making community to come together to learn, discuss, network and partner.

(March 2019)

Bio-Europe, Hamburg, Germany, November 11-13, 2019.

Xplico will be present at BIO-Europe 2019 in Hamburg, Germany on November 11^th to 13^th. BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry. In addition to productive partnering, BIO-Europe offers high level workshops, panels, company presentations, and a lively exhibition. Please contact us to book a meeting, either during the conference or at a time convenient for you, to discuss how you can benefit from our valuation services.

(August 2019)

BioFIT, Marseille, France, December 10-11, 2019.

Please meet us at the BioFIT conference in Marseille, France, in December 2019. BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing early-stage innovations stemming from public research institutions, academic spin-offs and emerging biotech companies. Together with big pharma, biotech and diagnostic companies, BioFIT operates as a platform to build partnerships for all public and private actors. (August 2019)

The new Xplico Evaluator template is now released

Xplico proudly releases a new and enhanced version of Xplico Evaluator, our valuation tool, available for all our subscription customers.

Many things have been changed behind the scene, with only a few changes in the way the assumptions are entered. The new version can handle more advanced Deal Terms and it has more features as well as additional outputs.

(June 2019)

Xplico named a "Gazelle Company" for the 3rd year in a row

We are delighted that the leading Danish business newspaper Børsen has named Xplico a 2018 Gazelle Company (a growth company) for the 3rd year in a row. Børsen analyses every year all the Danish companies to identify growth companies. A Gazelle company is defined by the growth in revenue every year for a minimum of four consecutive years. Further, the revenue needs to be doubled in the period of four years and the company must generate a profit. We plan to stay on the Gazelle list for the coming years. (December 2018)

Publication of the Xplico Valuation Survey

(November 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Finn Nikolajsen, gives his point of view on the challenges of the ownership structures that the biotech companies and their investors face when they try to analyze the consequences of current and future funding rounds and exits.

Read the full article

(October 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, gives his point of view on the challenges that the Nordic life science companies face.

Read the full article

(August 2018)

Xplico Interview with Biotech & Money / LSX

In an interview with Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, explains how valuation is critical for strategic decision-making and points out to some of the common pitfalls companies encounter when using valuation models that are built in house.

Read the interview

(June 2018)